Why is Hims & Hers Health stock down 3% today?

Traders Union
All News
Stocks
Hims & hers slides 3.08% today

Highlights

Hims & Hers Health expanded its men's health portfolio with new injectable and oral testosterone replacement therapies.
The company extended its online prescription weight management services into Germany via a digital health partnership, offering GLP-1 medications.
Shares of Hims & Hers Health trade below short- and medium-term moving averages with mixed momentum signals and a near-term range expected between $27.08 and $29.5.

Expansion in men’s health and lawsuit news fuel market uncertainty

Hims & Hers Health launched new injectable and oral testosterone replacement therapies for men, marking its largest expansion in men's health offerings since September. The company also broadened its online weight management services into Germany, providing prescription GLP-1 medications via a digital health partnership. A class action lawsuit alleging securities fraud against the company was reported and remains open for potential investors, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, views the technical setup as fragile. He sees the stock trading below key short- and medium-term averages and notes a weak trend with mixed momentum indicators. He highlights persistent selling pressure despite new therapy launches and the expansion into Germany. He warns that the unresolved class action lawsuit is a risk factor weighing on sentiment. "Given these pressures and the absence of strong technical support, I remain skeptical about near-term upside in HIMS," he states.

Viktoras Karapetjanc, expert at Traders Union, sees opportunity in the company's continued product innovation and international expansion. He believes the bullish long-term structure is intact, with the 50-day moving average above the 200-day. He expects further growth as new therapies broaden the customer base and strategic partnerships open up markets. He regards recent selling as a chance for patient investors. "With fundamental drivers aligning, I see potential for HIMS to outperform once technical resistance is cleared," Karapetjanc says.

Jainam Mehta, market strategist, notes Hims & Hers Health is consolidating between $27.08 and $29.5. He observes a balanced risk profile, as momentum signals do not show clear direction. Mehta suggests tactical traders watch for a potential breakout above resistance or a drop below support for new entries. "Sideways action offers contrarian opportunities for those watching $28.9 and $27.08 closely," he says.

Mixed momentum as price tests resistance amid bullish long-term bias

Hims & Hers Health is trading below its 20-day and 50-day moving averages ($29.2 and $29.18, respectively), showing ongoing short- and medium-term pressure from sellers. However, the price stays above the 200-day moving average ($27.2), with the 50-day above the 200-day MA, maintaining a bullish long-term alignment. The nearest levels to monitor are resistance at $28.9 and support at $27.54. Momentum indicators are mixed: MACD shows a sell bias, ADX points to a weak trend, RSI is neutral at 50.39 with a buy forecast, and both the Stochastic RSI and Commodity Channel Index are neutral. Bull/Bear Power is positive at 0.88, indicating intraday buyer dominance, but also suggesting overbought conditions. Intraday volatility is measured at 3.43%.

Previously it was reported that German market expansion and digital health partnerships, which had supported a bullish technical outlook. The current pullback, despite ongoing product launches, signals a shift in momentum and places emphasis on traders monitoring the $27.08 support level for any further downside risk.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.